Bonn University Team Reverses Human Cells' Age by Six Decades

A biomarker used to estimate cell age reversed by as much as 60 years in under two months, according to a study by researchers at Germany's Bonn University published in the journal Aging Cell and reported by WIRED. The team, led by stem cell professor Oliver Brüstle, reached that figure not by converting cells all the way into embryonic-like stem cells — the standard de-aging method since the mid-2000s — but by slowing the reprogramming process down enough to watch it happen in real time.

What did the Bonn researchers actually measure?

Brüstle's lab drew blood cells from donors across the age spectrum, including an infant and a 101-year-old, according to WIRED. The cells were guided toward a younger state using the same reprogramming genes that produce pluripotent stem cells, but the process was stopped short of full pluripotency. As the transformation progressed, the researchers tracked chemical signals in the cells' DNA — epigenetic markers that function as a biological clock — and recorded how far those markers moved backward.

How much did the cells' age reverse, and over what timeframe?

In less than two months of reprogramming, one of those biomarkers was set back as far as 60 years, the study found. The reversal continued even after the scientists sharply cut the cells' ability to multiply, according to WIRED's account of the paper — a control step meant to rule out a simpler explanation. If the de-aging signal had come from the cells simply dividing and refreshing themselves, slowing division should have slowed or stopped the reversal. It did not, which indicates the biomarker shift wasn't just a byproduct of cell turnover, though the researchers say the underlying mechanism driving the change remains unclear.

Data box: the numbers behind the study

• 60 years: maximum reversal recorded on one epigenetic age biomarker
• Under 2 months: time elapsed during the reprogramming process
• Age range of donors: from an infant to a 101-year-old
• 1: peer-reviewed journal publishing the findings — Aging Cell

Why does slow reprogramming matter compared with full stem cell conversion?

Scientists have been able to convert adult cells into pluripotent stem cells — cells capable of becoming nearly any tissue type in the body — for roughly two decades, Brüstle notes. But that method isn't usable as a therapy. "You don't want to have a pluripotent cell in your body, because it can become all types of cells," Brüstle told WIRED. The genes that drive the conversion can also trigger cancer if they stay switched on. By stopping the process before cells reach full pluripotency, and by slowing it down rather than letting it happen almost instantly, the Bonn team says it created a window to study de-aging step by step rather than as a single jump. "Now we can actually try to dissect the process much more easily than having an instantaneous event," Brüstle said.

What are the limitations of the blood-to-neuron conversion?

The Bonn team didn't just de-age blood cells — it also redirected them into a cell type that produces neurons. That introduces a measurement wrinkle: blood cells and neurons age on different biological timelines, so comparing an aging biomarker across cell types could overstate how much reversal actually occurred, the researchers acknowledge in the paper, as reported by WIRED. Still, the authors say that discrepancy can't account for all of the age-associated markers that shifted. Separately, turning blood cells into neuron-producing cells would be an unwanted side effect in a patient given a hypothetical de-aging drug, though the researchers say it could prove useful for other regenerative medicine applications.

Timeline of the experiment

• Start: Blood cells collected from donors ranging from an infant to a 101-year-old
• Early reprogramming: Cells guided toward a younger state using pluripotency-associated genes, stopped short of full conversion
• Under 2 months in: One epigenetic biomarker measured as reversed by up to 60 years
• Control step: Cell division sharply reduced; aging reversal continued regardless
• Nov. 11, 2026: Findings detailed by WIRED following publication in Aging Cell

What happens next for de-aging research?

Brüstle says the ultimate goal is applying the approach "systemically in the entire animal," but he's cautious about jumping to patients before the biology is better understood. "If you think about applying it in a patient, then you want to be sure this is not a lab experiment, so it's about finding the mechanism," he told WIRED. That mechanism — what specifically erases the aging signals during the slow reprogramming window — is still unidentified, which the Bonn team flags as the next research priority before any therapeutic application can be considered.